PD-L1 Mediates IFNγ-Regulation of Glucose but Not of Tryptophan Metabolism in Clear Cell Renal Cell Carcinoma.
CD274)
PD-L1 (B7-H1
clear cell renal cell carcinoma (ccRCC)
glycolysis
interferon gamma
kynurenine
metabolism
tryptophan
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
01
2022
accepted:
13
04
2022
entrez:
3
6
2022
pubmed:
4
6
2022
medline:
4
6
2022
Statut:
epublish
Résumé
The immune checkpoint programmed death-ligand 1 (PD-L1) is expressed on the cell surface of tumor cells and is key for maintaining an immunosuppressive microenvironment through its interaction with the programmed death 1 (PD-1). Clear cell renal cell carcinoma (ccRCC) is a highly immunogenic cancer characterized by an aberrant aerobic glycolytic metabolism and is known to overexpress PD-L1. Multiple immunotherapies have been approved for the treatment of ccRCC, including cytokines and immune checkpoint inhibitors. Recently the intrinsic role of PD-L1 and interferon gamma (IFNγ) signaling have been studied in several types of tumor cells, yet it remains unclear how they affect the metabolism and signaling pathways of ccRCC. Using metabolomics, metabolic assays and RNAseq, we showed that IFNγ enhanced aerobic glycolysis and tryptophan metabolism in ccRCC cells
Identifiants
pubmed: 35656514
doi: 10.3389/fonc.2022.858379
pmc: PMC9152103
doi:
Types de publication
Journal Article
Langues
eng
Pagination
858379Informations de copyright
Copyright © 2022 Garige, Ghosh, Norris, Li, Poncet, Chou, Wu, Shen and Sourbier.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Semin Oncol. 1995 Feb;22(1):3-8
pubmed: 7855617
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Genome Biol. 2015 Mar 31;16:64
pubmed: 25853550
Cell Rep. 2021 May 25;35(8):109181
pubmed: 34038737
Blood. 2019 Nov 21;134(21):1832-1846
pubmed: 31511238
Nat Genet. 1994 May;7(1):85-90
pubmed: 7915601
Sci Transl Med. 2013 Aug 28;5(200):200ra116
pubmed: 23986400
Nat Rev Cancer. 2015 Jan;15(1):55-64
pubmed: 25533676
Blood. 2007 May 1;109(9):3812-9
pubmed: 17255361
Eur Urol. 2016 Apr;69(4):646-657
pubmed: 26298207
Cell. 2015 Sep 10;162(6):1229-41
pubmed: 26321679
J Neuroinflammation. 2018 Oct 17;15(1):290
pubmed: 30333036
Front Immunol. 2018 Jan 31;9:151
pubmed: 29445380
J Biol Chem. 2006 Jun 16;281(24):16768-76
pubmed: 16608839
Int J Mol Sci. 2017 Dec 28;19(1):
pubmed: 29283429
Front Immunol. 2020 Oct 21;11:568931
pubmed: 33193345
BMC Genomics. 2018 May 4;19(1):326
pubmed: 29728062
Oncogene. 2012 Jul 19;31(29):3467-81
pubmed: 22105366
Nat Commun. 2017 May 10;8:15207
pubmed: 28488695
J Immunol. 2011 Jul 1;187(1):126-32
pubmed: 21632715
Science. 1993 May 28;260(5112):1317-20
pubmed: 8493574
Cell Stress. 2020 Jan 03;4(1):24-26
pubmed: 31922097
FASEB J. 1991 Aug;5(11):2516-22
pubmed: 1907934
Nat Rev Nephrol. 2020 Dec;16(12):721-735
pubmed: 32733094
Annu Rev Pathol. 2015;10:473-510
pubmed: 25621663
Medicine (Baltimore). 2020 Aug 21;99(34):e21693
pubmed: 32846785
Nat Rev Immunol. 2009 Mar;9(3):162-74
pubmed: 19197294
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Cancers (Basel). 2019 Sep 25;11(10):
pubmed: 31557897
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Immunol Lett. 2007 Aug 15;111(2):69-75
pubmed: 17644189
Br J Cancer. 2020 Jul;123(1):137-147
pubmed: 32390008
Cancer Res. 2014 Jan 1;74(1):8-14
pubmed: 24362915
Cell. 2017 Jun 29;170(1):127-141.e15
pubmed: 28666115
Semin Cancer Biol. 2013 Feb;23(1):18-25
pubmed: 22705278
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214
pubmed: 33437048
Endocr Relat Cancer. 2010 May 18;17(2):481-93
pubmed: 20233708
Oncoimmunology. 2012 May 1;1(3):261-262
pubmed: 22737600
Urol Oncol. 2017 Jul;35(7):461.e15-461.e27
pubmed: 28359744
Front Pharmacol. 2017 Aug 23;8:561
pubmed: 28878676
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancer Res. 2011 Oct 15;71(20):6400-9
pubmed: 21900394
Diabetes. 2007 Jan;56(1):72-9
pubmed: 17192467
Nature. 2013 Jul 4;499(7456):43-9
pubmed: 23792563
Cell. 2016 Dec 1;167(6):1540-1554.e12
pubmed: 27912061
Cancer Immunol Res. 2015 Oct;3(10):1148-1157
pubmed: 26014098
J Exp Clin Cancer Res. 2019 Nov 12;38(1):462
pubmed: 31718692
Int J Mol Sci. 2020 Apr 05;21(7):
pubmed: 32260578
Proc Natl Acad Sci U S A. 1996 Jul 23;93(15):7673-8
pubmed: 8755534
J Immunol. 2009 Apr 15;182(8):4499-506
pubmed: 19342621
BMB Rep. 2021 Jan;54(1):12-20
pubmed: 33298250
Int Immunol. 2016 Aug;28(8):401-9
pubmed: 27160722
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Eur J Immunol. 2008 Sep;38(9):2438-50
pubmed: 18792400
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
JCI Insight. 2021 Apr 22;6(8):
pubmed: 33884962
Nat Med. 2003 Oct;9(10):1269-74
pubmed: 14502282
Nat Rev Urol. 2016 Feb;13(2):65
pubmed: 26754191